A new discipline, cardio-oncology, has emerged as a major clinical need over the last decade as a result of novel cancer therapies that are associated with cardiovascular complications (1) . Direct myocardial toxicity is particularly relevant to cardio-oncology, especially because this phenomenon was appreciated more than 50 years ago with anthracyclines (1, 2) . Anthracyclines, such as doxorubicin, have been effective as cornerstone therapies for multiple cancer types, but have been associated with clinical heart failure or cardiomyopathy.
Anthracycline-induced cardiac toxicity is felt to be cumulative and dose-dependent, and can present acutely (within days to weeks of a treatment) but is more commonly recognized as a subacute cardiomyopathy (occurring months to years later). Cardiomyopathy is a major toxicity with this class of drugs and limits their use. Myocardial protection is an important potential strategy for attenuating cardiotoxicity, especially in high-risk patients (2) . In this regard, several studies, mostly performed in the pediatric cancer population exposed to anthracyclines, suggest a cardioprotective role for dexrazoxane, an iron chelator. However, the role of neurohormonal activation in the progression of typical adult heart failure is well described, and the beneficial effects what the authors have done for this paper. In the long term, this will better inform preventive and treatment strategies for patients.
